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 Abstract:  
 
In this work we present a method for the statistical analysis of continually monitored 
data arising in a recurrent diseases problem. The model enables individual level 
inference in the presence of time transience and population heterogeneity. This is 
achieved by applying Bayesian hierarchical modelling, where marked point processes 
are used as descriptions of the individual data, with latent variables providing a means 
of modelling long range dependence and transience over time. In addition to providing 
a sound probabilistic formulation of a rather complex data set, the proposed method is 
also successful in prediction of future outcomes. Computational difficulties arising 
from the analytic intractability of this Bayesian model were solved by implementing 
the method into the BUGS software and using standard computational facilities. 
 
We illustrate this approach by an analysis of a data set on hormone replacement 
therapies (HRTs). The data contain, in the form of diaries on bleeding patterns 
maintained by individual patients, detailed information on how they responded to 
different HRTs. The proposed model is able to capture the essential features of these 
treatments as well  as provide realistic individual level predictions on the future 
bleeding patterns.  
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 1 Introduction  
      
Time in-homogeneous data, in particular transience, are frequently  encountered  in 
repeated events  contexts arising in clinical, biomedical and engineering research 
problems. Such applications often require further attention to modelling or explaining of 
cross-sectional heterogeneity due to known or unknown background  factors/covariates. 
Box-Steffensmeier and De-Boef (2002)  carried  out  a Monte Carlo comparison  of 
several event  history  models. They  concluded  that  the  models that  do well  under  
heterogeneity  don’t  necessarily do well with added event  dependence, and  similarly 
models that  do well under  event  dependence  do not also handle heterogeneity well. 
However it has also been shown that inference quality could suffer if either between 
subject or within subject heterogeneity is not accounted for (Kaplan et al 2009). 
Considering both  types of dependence jointly presents new challenges for analysts 
(Torá-Rocamora et al 2013, Bijwaard 2011, Box-Steffensmeier and De-Boef 2006).  
 
There is an extensive literature available on recurrent event data, (ref.  Cox 1963, 
Ascher and Feingold 1983).  Many model variations  based on the Cox proportional 
hazards model have also been proposed for the analysis of repeated events (Clayton  
1994, Lin 1994, Gao & Zhou 1997, Klein & Moeschberger 1997, Therneau & Hamilton  
1997, Wei & Glidden 1997, Hosmer & Lemeshow 1999, Kelly & Lim 2000, Box-
Steffensmeir & Zorn 2002). Most of these fall short in capturing the individual/subject  
level features (in absence of usable covariates) in such problems. Keeping in view 
today’s demand to aid personalized medicine, our objective would be not only to model 
such recurrent data, in presence of transience and heterogeneity, but also to reliably 
estimate future outcome trajectories to aid medical decision making. 
 
In the following we focus on description of the data to highlight the complexities 
involved in the problem. Here we consider data  arising from the field of clinical 
medicine, where the subjects experience repeated  relapse of the event. However, at 
least  in part due to the treatment which they are actually undergoing, their condition is 
expected to gradually  improve over time.  We propose a model to analyse bleeding 
pattern of different HRTs, as described by the bleeding  diaries maintained  by 
individual  women receiving the  treatment.   
 
The biological event of menopause signifies an important change in every woman’s life. 
As menopause approaches, a woman’s ovaries start  producing less of the female 
hormones - oestrogen and progestogen.  Conditions  like osteoporosis    develop after  
menopause  because women lose the  protective  effect of oestrogen.  Hormone 
replacement  therapy  (HRT)  is a medication  where oestrogens or a combination  of 
oestrogens and  progestogens  is  applied  for the  treatment of climacteric symptoms 
and, for example, for the prevention of osteoporosis. HRTs are known to lead to a 
significant reduction  in the incidence of hip and forearm fractures.  
HRT  is now available  in many  different  forms and  variations.  In  order  to  
prevent endometrial  cancer, women with a uterus  are advised to combine oestrogen 
replacement therapy  with  one  of the  many  different  progestogens  available,  either  
in a continuous daily regimen or sequentially,  in a monthly  or (more experimentally)  
quarterly  regimen.  Despite the benefits of HRT to postmenopausal  women, a large 
proportion of the women who start  HRT discontinue the therapy after a year, and by 
three years most patients  have done so, due to the occurrence of unwanted  uterine  
bleeding (Hahn 1989, Nachtigall 1993, Hammond  1994, Goldman et al 1998). 
 
The bleeding pattern needs to be studied for two major reasons: firstly to understand 
the  course and  outcome of the  therapy  itself, and  secondly to improve patient  
adherence. Since unwanted  bleeding accounts  for a high percentage  of adherence  
failures, it is necessary for health  care professionals to familiarize themselves with 
these bleeding data and their  inherent pattern. 
 
  Bleeding develops regardless of whether  the combination  regimen used is sequential  
(Sequential combined HRT: scHRT), that usually produces a regular and therefore 
predictable  bleeding pattern, or continuous administration of the two hormones (known 
as Continuous combined HRT: ccHRT), producing a much less predictable  bleeding 
pattern. In order to address this common concern, it is necessary for clinicians to 
decipher the uterine bleeding data  on as many HRT  products  as possible, to be able to 
guide and  assure the  patients regarding the course and outcome of the treatment which 
they receive (Ravnikar 1987, Kadri 1990, Wren and Brown 1991, Ryan et al 1992, Barentsen 
et al 1993). 
 
Of the different types of HRT, scHRT’s could be the less preferred option as they 
induce a menstrual  like withdrawal  bleeding occurring towards the end of, or not long 
after,  the progestogen phase.  Also in scHRT, bleeding lessens after several years of 
treatment, and hence many postmenopausal  women are  unwilling to accept  such 
bleeding episodes for such an extended  period of time. 
 
ccHRTs were developed as an alternative  to sequential treatments, to improve patient 
adherence  by improving bleeding control.  Continuous  administration of progestogens 
or other  compounds  in  combination with  oestrogen  has  been advocated as a means 
to  avoid the scheduled withdrawal  bleedings associated with scHRT regimens. ccHRTs 
generally lead to less frequent and shorter bleeding episodes, but unlike in scHRT, they 
are not periodical. 
 
The effect of different HRT regimes can be also characterised in terms of lack of 
bleeding. There  are several measures to quantify  such developments,  most of which 
are characteristics only at individual time points.  In order to predict  the chances of 
bleeding cessation with  continued  HRT  use, summary measurements  need to be 
formed which describe effects over prolonged treatment intervals.  A parameter  that  
has been used frequently  in recent years is “Cumulative  amenorrhea”, defined as 
absence of bleeding or spotting  for a continuous period of time, say three or six months. 
 
2 Preliminary Exploration of Data 
 
Bleeding information  is usually  collected  in  the  form  of diaries,  each  diary  
recording bleeding  incidents  during  90 consecutive days.   Here we consider a data  
set containing information  on three different HRTs, two of which are continuous 
combined (i.e. ccHRT) whereas the third  one is sequential  (i.e.  scHRT).  Data  on 163 
subjects were collected for approximately  one year (4 diaries).   Of these 163 subjects,  
54 received ‘type-1’  ccHRT, 56 received ‘type-2’ ccHRT, and the remaining 53 were 
given scHRT.   
 
He it may be noted that there is another form of diary data where the events are 
recorded in a nested manner within each day. This often gives rise to a multi-level 
organisation of the data (or events of interest) and requires different methods of analyses 
(see for example Roesch et al 2010). 
 
Additionally  we have data  from another  experiment  carried  out  five years prior to 
the  above trial,  where the  type-1  ccHRT was applied  on 48 subjects and  data were 
collected for two years (referred  to as ‘second data  set’ henceforward).   We use this 
latter  data set for validation  and prediction purposes.  In both data  sets, while most 
subjects completed the studies, for a few the treatment and follow-up study had to be 
terminated due to various reasons. 
 
Next we observe that the nature of bleeding can vary in magnitude.  The common 
practice has been to dichotomise the level into two categories,  called “Bleeding”  and 
“Spotting”, where spotting  is the lesser in discomfort of the two.  In the diaries, each 
date was marked with letter  “B” if the patient experienced bleeding, with “S” if she 
experienced spotting,  and it was left blank otherwise (which will be marked by “N” in 
this analysis). 
  
Depending on the focus of interest,  HRT related  data  can be presented  and 
summarised in a number  of  different ways.  For example,  one can consider, for each 
subject,  the percentage  of days with bleeding, spotting,  and neither  bleeding nor 
spotting.  As an alternative, one can consider, at a given time point,  the number,  or 
proportion, of subjects  with bleeding, spotting  and neither, etc. We computed  for the 
second and smaller    data set the proportions  of days spent by each individual  in each 
of the respective states  “B”, “S” and “N”. As expected, with an exception of a few, the 
majority of the subjects spent more than  80 percent  of their  time  in state  “N”, i.e.  
they  were free from both bleeding and spotting  (result  not shown). 
 
However, it may well be the case that  different subjects report  comparable  values 
for summary statistics,  but then a closer inspection reveals that  the number of 
corresponding episodes is markedly different.  In the following the percentage  of time 
spent in the states “B”, “S” and “N”, along with the  total number  of such episodes is 
presented  for three (randomly)  selected subjects from the same data  set (Table 1).  The 
durations  of the  episodes spent in these three states,   for these same  subjects, are 
presented  in Figure 1. 
(Table 1 approximately here) 
 (Figure-1 approximately here) 
 
This suggests that  every time a subject  enters  a state  not  only the  type of the  
state, i.e. “B”, “S” or “N”, but also the duration  in that  state  as well as the order in 
which they occur, should be considered for a proper understanding of the course of the 
treatment. 
 
As was mentioned  before, for patients  who develop uterine  bleeding after  initiation  
of HRT,  data  on  cumulative  amenorrhea  is thought  play an important  role in 
enabling  a physician to predict  the  chances  of bleeding cessation  with continued  
HRT  use.  Thus, cumulative  amenorrhea  can provide the clinician  with valuable  
information  that  can be used to help patients  to select the HRT best suited to their 
needs. In order to understand the  situation  better  we carried  out  a preliminary  
analysis of the  bleeding/spotting  free “N” episodes. 
 
In Figure 2 we present several summaries of the “N” episode from the second data  
set. Top-left panel:  This plot shows that  the number of “N” episodes experienced by 
patients varied widely.  Top-right panel:  The  number  of “N” episodes varied 
irrespective of total length of “N” days, (e.g. one patient experienced no bleeding or 
spotting during the entire study  period of 720 days, whereas another  patient 
experienced 46 “N” episodes within a total  of 530 “N” days).  Bottom-left  panel:  For 
any given subject the “N” episode lengths varied  highly, with  several patients  
experiencing maximum episode length of more than few hundred  days as well as 
minimum of only a few days. Bottom-right panel:  For many subjects there was no 
apparent trend  in the “N” episodes. 
 
(Figure-2 approximately here) 
 
The top panel plots indicate that  there is a high degree of heterogeneity across 
subjects. The  bottom  panel  shows that  there  can be large variation  in the  duration  
of the  “N” episodes within a subject, and there is no obvious trend over time.  However, 
the treatment is known to have long term  benefits and  patients  are generally expected  
to experience gradually  longer “N” episodes. It would therefore seem that the speed of 
improvement is different from patient to patient and needs to be monitored  and 
modelled individually  to understand the underlying  pattern (Fig. 3). 
 
(Figure-3 approximately here) 
 
3 Model and analysis 
 
From the preceding discussion it is apparent that  in order to provide a realistic 
description of the  bleeding  diary  data,  and  also to  lead to  useful individual  level 
predictions,  the statistical model should respect the following desiderata: 
- it should be able to describe adequately  the alternating transitions between the non-
bleeding and the bleeding and/or spotting  phases; 
- it should have the ability  to adjust  itself to the widely different ways in which 
individual women respond to HRT, also accommodating  the large amount of variation  
that  is seen in the duration  of the bleeding and non-bleeding episodes even for the 
same woman; 
- it should have the  potential  of describing the  expected  development towards  
cumulative  amenorrhea, but  allowing for the  fact that  this  may happen  individually  
at  very different speeds; 
- given these desiderata  and the limited  amounts  of data,  the model structure should 
be as simple as  possible, to  enable the  estimation  of its parameters with  a reasonable 
accuracy, as well as provide realistic individual  level predictions  regarding  the  
cessation of bleeding. 
 
Our  first  choice towards  a  simple  model  structure concerns  the  way  in  which  
the episodes of  non-bleeding, bleeding and spotting  registered  in the diaries are dealt  
with. Instead of considering a three state model in which the states would correspond 
directly to the non-bleeding,  bleeding and spotting episodes, we lump the possibly 
several consecutive episodes of bleeding and spotting  that  may occur between two 
adjacent non-bleeding episodes into a single combined episode.  In other  words, we 
consider  the episode starting from the time at  which a previous non-bleeding episode 
ends, and either  bleeding or spotting  begins, until  the  woman enters  again  the  non-
bleeding  state.   However, in order to arrive at a sufficiently fine description  of this  
process, we divide such a combined response further  into three  types:  in a “B”  
episode there  is bleeding, but  no spotting, between two adjacent non-bleeding  (“N”)  
periods,  in an “S” episode there  is only spotting but  no bleeding, and  in a “BS” 
episode there  are one or more consecutive spells of both  bleeding and spotting  without  
an intermittent non-bleeding period.  (Note that for every completely  observed duration  
in the  “lumped  B/S/BS” state  it will ultimately  be clear how it should be classified 
further  according to the finer “B”-, “S”- and “BS”-scale, but  from right censored data it 
may be impossible to distinguish  between the  “B”- and “BS”-categories  on the one 
hand,  and between “S”- and “BS”-categories  on the other.) 
 
Another  natural thought towards  satisfying  the  above desiderata  is to employ a 
hierarchical model structure where, in addition  to the  observed alternating durations  in 
the “N” and “B/S/BS” states,  there is a latent process that  would, in a sense, 
correspond to the woman’s “physiological state”  at any given time.  The individually 
different responses over time to the HRT could then  be attributed to individually 
different sample paths  of this  underlying  process.  Although,  in principle,  it would be 
natural to consider such an underlying  state  as a continuous variable, it seems that  
considering k such states, and  ordering them  in an appropriate way, will be sufficient  
for an adequate  enough description. In this particular example we have used k = 4, 
where one state  which (on the observed level) has the  tendency  of leading to short 
durations  in the “N” phase,  another  state  in which the durations  in the “N” phase are 
(stochastically) somewhat  longer, a third  one in which  they  are longer still, and 
finally a fourth  one in which “N”  is “nearly  absorbing”.   To roughly approximate an 
underlying continuous behaviour through a finite number of states, perhaps 3 states in 
general would be enough, viz. short, medium and long duration. However, for the 
present data where extreme heterogeneous nature of the data raises the possibility of 
observing a really long duration equivalent to no relapse to B/S/BS states, necessitates 
introduction of at least another state, thus leading to the choice of k = 4.  
 
In the following we denote these states by N4, N3, N2 and N1, respectively, with N1 
being the “nearly absorbing” state. For  a woman,  whose  diary  initially documents 
short durations  in the “N”-state, in-between “B”-, “S”- or “BS”-episodes, and is then  
progressively moving towards amenorrhea,  we would expect the underlying  state 
process to move similarly from N4 to N1.  Apart from providing a description of such 
transience in the response of an individual woman to the HRT received, this 
combination of an observed and an underlying process can be expected to act in the role 
of a “memory” capturing  the essential features of the past recorded history in the diary, 
and thereby acting as a convenient summary  on which the future  dynamics can be 
conditioned. 
 
A natural suggestion,  based  on the  considerations  above, would now be to describe 
the  status  of an individual  woman at  time t (when measured  from the  beginning  of 
the treatment)  by a pair of random  variables,  say (Ot, Lt).  Here Ot   is the  observed 
status  determined  from the  available  diary  data  and  assuming  one of the  four 
possible values “N”, “B”, “S” and “BS”, and Lt  is the corresponding unobserved 
(latent) status  variable with the possible values 1, 2, 3 and 4 as described above. Recall 
that  the observed process (Ot) is alternating in the sense that  after every two transitions 
it has to be back in state “N”. In order  to arrive at  a sufficiently simple probabilistic  
description  of the  bivariate process (Ot, Lt) we now postulate that  transitions in the  
latent process (Lt) can  only happen  at  times  at  which the process (Ot) returns  to the 
state  “N”.  It would then  be attractive to postulate further  that  the  bivariate  process 
(Ot, Lt) has a hidden  Markov structure, with (Lt) as the “hidden  layer”.  Unfortunately, 
already a preliminary  analysis of the diary data  showed that  this would not be realistic, 
in the sense that  even with the latent variable  (Lt) included as a part  of the  “current  
state”  description  its  knowledge would not provide an adequate  basis for predicting  
the future  behaviour  of the observed process  (Ot).  Therefore  we need to extend  the 
“memory”  from the current state  of the process (Ot, Lt) to include also some relevant 
aspect of its history. 
 
Although not necessarily Markov, (Ot, Lt) nevertheless has the structure of a bivariate 
jump process, or marked point process, and its probability  distribution can be specified 
in terms of conditional mark specific intensities for the “next”  transition, always 
conditioned on the past  history  of that  process.  Because of its “jump-like”  character,  
we can specify such  a model either  by relating  the  intensities  directly  to  the  follow-
up time t of the considered woman, or by indexing the episodes according to their 
natural ordering in time, corresponding to observed levels of constancy  in the process 
(Ot), and then  also  taking into account the durations  of such episodes together  with 
the relevant status  information. Thus,  if 0 = T0 < T1 < T2   < . . . are  the  times  at  
which the  observed  status Ot of an individual  woman changes, we specify a sequence 
X1 , X2 , . . . of random  durations  by Xj  = Tj − Tj−1, j ≥ 1. 
 
We also change  somewhat  the  way in which the  status  was described,  that  is, by 
jointly  considering  Ot and Lt.  First,  we define a corresponding sequence I1 , I2 , . . . of 
“phase  indicators”  by letting  Ij = 1  if the j-th episode was in an “N” state,  that  is, if 
Ot = “N” for t ε  [Tj−1, Tj), and otherwise let Ij = 0. We then  define the sequence C1, C2, 
. . . by setting  
. 
 
Note that,  since the  processes (Ot) and  (Lt) always remain  constant  on intervals  of 
the form [Tj−1, Tj), we can say that  the variables in the sequence (Cj) alternate between 
defining an observed or a latent state:  during an “N” episode it is identical  to the 
corresponding latent status,  and during a bleeding and/or spotting  it specifies the type 
(“B”, “S” or “BS”) of this episode. 
 
The remaining  task  is to specify the conditional  intensities  governing these 
processes. In order to simplify matters, we postulate that  all such intensities  are 
constant over the corresponding episodes, thus  giving rise to conditionally  independent  
exponential  durations in the corresponding states.  Taking into account the earlier 
remarks on the necessity of including some additional  “memory”, in order to describe 
the non-Markovian character  of these processes, we have the following two situations  
to consider: 
 
(i) If the  woman is currently,  at  time  t ε [Tj−1, Tj), in an “N” state,  so that  the  
corresponding  phase indicator  then  has the  value Ij = 1, we assume that  the  intensity  
of leaving that  state  can depend on the corresponding (latent) state Cj. Furthermore, 
when this transition into the new state Cj+1 (being then  one of the states  “B”, “S” and 
“BS”) actually  happens, we allow the transition probabilities  to depend, in addition  to 
the current (latent) status  given by Cj, also on the (observed) status Cj−1 during the 
immediately preceding bleeding and/or spotting  episode. 
 
(ii) If she is currently,  at time t ε [Tj−1, Tj), in one of the observed states  “B”, “S” 
and “BS”, so that  the corresponding phase indicator  then  has the value Ij = 0, we 
assume that  the  intensity  of leaving  that  state  can depend on the  current  (observed)  
state Cj. Furthermore, when this  transition into the new state Cj+1 (being then  one of the 
latent states  1, 2, 3 and 4) actually  happens, we allow the transition probabilities  to 
depend, in addition  to the current (observed) status  given by Cj, also on the 
corresponding (latent) status  given by Cj−1. 
 
Thus we could say that  this model assumes a “second order memory” structure. Given these as 
guidelines, we now specify a corresponding hierarchical  Bayesian  model for the bleeding  diary  
data. In  doing  so,  we need  to  specify also prior  distributions for the necessary model 
(hyper)parameters.  In  addition,  we have to account  for the  fact that  there were altogether  163 
women (now indexed by subscript i) with individually  different observed and latent status  histories, 
and three different types of treatment (here indexed by symbol Tr).  
 
3.1 Model summary:  
Here is a summary  of the model specification: 
 
1. Duration j of subject i: 
        (Xi,j  | Tri, Ii, j, Ci,j, β(Tri, Ii, j, Ci,j)) ~ Exp( β(Tri, Ii, j, Ci,j)), where i = 1, . . . , 163 and j ≥ 1, 
 2. Therapy  variables (observed):  
        Tri = 1, 2, 3 indicating  type of HRT given to subject i 
 
3. Phase  variables:  
        Ii,1 | Tri ~ Bernoulli( P00(Tri)) and 
        Ii,j = 1 − Ii,j−1  where i = 1, . . . , 163 and j ≥ 2, 
 
4. Partially latent state  variables:  
         (Ci,1  | Tri, Ii,1 P0 ) ~ Multinomial(1, P0 (Tri , Ii,1 )), 
         (Ci,2  | Tri, Ii,2 P0 ) ~ Multinomial(1, P0 (Tri , Ii,2 )), 
         (Ci,j   | Tri, Ii,j, Ci,j−1 , Ci,j−2 , P) ~  Multinomial (1, P(Tri , Ii,j, Ci,j−1, Ci,j−2)) , 
        where i = 1, . . . , 163 and j ≥ 3, 
 
5. State  specific intensities:  
        β1,0,l = β2,0,l = β3,0,l  ~  Gamma(0.1, 0.1), where l = 1, 2, 3 and 
        βtr,1,1  ≡ 0.00001, 
        βtr,1,l  ~  Gamma(0.1, 0.1), where tr = 1, 2, 3, l = 2, . . . , k and 
        βtr,1,1  ≤ βtr,1,2  ≤ . . . ≤ βtr,1,k−1  ≤ βtr,1,k, 
 
6. Transition probabilities:  
        P(tr, 0, l1, l2; . ) ~ Dirichlet(I0), where tr = 1, 2, 3, l1  = 1, . . . , k, and l2 = 1, 2, 3, 
        P(tr, 1, l1, l2; . ) ~ Dirichlet(I1), where tr = 1, 2, 3, l1  = 1, 2, 3, and l2 = 1, . . . , k, 
 
7. Initial  distribution:  
        P0(tr, 0; .) ~ Dirichlet(10) 
        P0(tr, 1; .) ~ Dirichlet(11) 
        where tr = 1, 2, 3, 10  = (1)3×1  and 11  = (1)k×1, 
 
8. Phase  probabilities:  
        P00(tr; .) ~ Uniform(0, 1) where tr = 1, 2, 3. 
 . 
  
The fixed parameters in the  model were  chosen so as to  give rise to  reasonably vague priors.   The  
numerical  estimation  of the desired parameters and other  quantities  was carried  out using Markov 
Chain  Monte Carlo (MCMC)  method,  by drawing a large MCMC sample from the  posterior  
distributions of the  parameters.  The  model was specified in BUGS language and implemented  in 
WINBUGS.    
 
4 Results: 
 
4.1 Estimation of the structural and population parameters: 
 
The characterising differences between the two types of HRT, viz. continuous combined (cc) and 
sequential combined (sc), are already visible in the estimated  initial probabilities for being in an “N” 
or a non-“N” state (Table 2)  The differences between the two types of ccHRT were negligible.  
However, as for scHRT bleeding or spotting  occurs mostly around  the time of progestine  
application,  initially most subjects (in the present data  98%) could be predicted to be in the “N” 
phase. 
 (Table 2 approximately here) 
 
At the initiation  of the ccHRT the subjects in the non-“N”  phase mostly start  with spotting, i.e. 
in the “S” state (Table 3).  A closer inspection reveals the heterogeneous nature  of the study sample 
at  the beginning of the treatment. The estimates  for the scHRT appeared  to be well in line with the 
existing knowledge of the  behaviour  of this type  of therapy,  which induces a rather  regular and 
menstrual  like response in the subjects. 
(Table 3 approximately here) 
 
So far, based on the  initial  phase and  latent state  distributions, the  two ccHRTs had not  shown 
any  noticeable  difference.  However, the  intensity  estimates  (Table 3) brought  out  some 
interesting  differences between the two.  Subjects receiving Type-1 ccHRT would be expected to 
experience much shorter  bleeding episodes than  those receiving Type-2 ccHRT (the respective 
intensity estimates of leaving the S-state being 0.75 and 0.29.) . The pattern of estimates  for scHRT 
was again different from those for ccHRTs, the most noticeable difference being in the expected 
duration of the “SB” episodes.  
 
In the following the  estimates  of the  two-step  transition matrices  are presented  for all three  
treatments and two phases (Table 4).  Recall that  even though  the patient’s  condition  is generally 
expected  to improve over time, a preliminary  examination  of the data had not shown any readily 
recognizable trend in this respect.  Therefore, due to lack of evident trend  over time, we did not 
impose any a priori monotonicity  condition on the transition matrix. We had also assumed vague 
priors on the transition probability  matrices. Nevertheless, the posteriors  show noticeable  patterns. 
(Table 4 approximately here) 
 
Of the two ccHRTs, the transient nature  of  type-1 ccHRT can be seen clearly. For example, a 
woman initially in the latent non-bleeding state N4 could be expected, with probability 0.31, to be in 
a “better” state N2 after having subsequently again returned to a non-bleeding phase, and then with 
probability 0.35 in state N1 after the next return.  For type-2 ccHRT, the chance of remaining in an 
initial state N4 seemed somewhat higher than for type-1. Otherwise, however, the transient 
behaviour of  moving towards the better  states was even clearer in type-2 . 
 
Based on the medical background behind scHRT, subjects undergoing this therapy  are expected 
to experience episodes in state  “N” of approximately  the same length each and improvement only 
over long term.  Note that  the estimates also predict the same, although no such a priori assumptions  
or restrictions were imposed on the relevant parameters. 
 
The two ccHRTs show noticeably different trends for the bleeding and spotting episodes. Type-1  
ccHRT shows much higher probabilities  for transition to a bleeding episode, compared to those 
under type-2 ccHRT. However, recall that  the bleeding episodes under type-1  ccHRT  were 
predicted  to be very  short  since the intensity  estimate of leaving that state was much larger than  
all the others. 
 
For  the  scHRT,  irrespective of the  current “S/SB/B” episode type there  is high possibility for 
transiting to an “SB” state  in the  next  cycle.  However, the  estimated  intensity associated  with 
“SB”  episodes for subjects under  scHRT was also comparatively  higher, indicating that  the 
expected durations of the episodes in that  state  are shorter than  those experienced under ccHRTs. 
 
 
4.2  Prediction for  generic individuals: 
In order to provide useful summaries  of the estimated  complex model, we computed  predictive 
distributions for the event processes for generic individuals  assumed  to undergo different HRTs.  
The posterior means of the model parameters presented above in the Tables 2, 3 and 4 were used to 
simulate  these processes. The prediction  period was the  first year of the  therapy.   The  simulated  
processes can be summarised  in several different ways.  In the  following we present the  
corresponding predictive probabilities  for being in  state  “N” for a generic individual,  considered at  
different  time points during this one year. 
 
Although  initial  data  explorations  had  not  revealed any systematic  trend  of moving towards 
amenorrhea,  the predictions  for a generic individual  clearly indicated  this  to be the case (Figure-
4).   This  became evident  already  from the  parameter estimates  for type-1 and type-2 ccHRT. 
Subjects receiving ccHRT were predicted  to improve quite fast over the one year period,  whereas 
corresponding predictions  for scHRT  show no, or only a very slow trend. 
 
(Figure-4 approximately here) 
 
As mentioned  before, the  effects of different  HRT  regimes can be also characterised  in terms  
of lack  of bleeding.  In order to predict  the chances of bleeding cessation with continued HRT use, 
measures need to be used which describe effects over prolonged treatment intervals.  For the  
purpose of analysis,  cumulative  amenorrhea  was defined to be absence of any bleeding or spotting 
for a period of 180 consecutive days (approximately six months),  and similarly the waiting time to 
cumulative amenorrhea  was defined as the time to last bleeding or spotting  that  is then followed by 
absence of it for more than  180 days.   
 
Table 5 provides a brief summary  of the results that  were obtained,  in terms of the median and 
the mean of the predictive distribution for the waiting time to cumulative amenorrhea. The  results  
also showed that,  once cumulative  amenorrhea  is achieved it is also usually sustained  for quite 
long. 
(Table 5 approximately here) 
 
We also investigated,  not only the time till cumulative amenorrhea  is achieved, but the nature of 
progression during the waiting time under the different HRTs.  For this purpose, the simulated  
processes were used to predict  the percentage  of time spent in the different states,  i.e.   the  
proportions  spent  in  different  latent “N”  states  and  in the  “S/SB/B” states (see Table 5 for 
summary results). 
 
 Predictive distributions for the residual time to the next relapse at pre-determined time  points  
and  for different  subjects were also computed.   Judged  from these  predictive distributions, the 
residual times appear to be stochastically  ordered.  In other  words, the more time has  elapsed from 
the beginning of the treatment, the longer, in the sense of stochastic  ordering, it takes to the next 
relapse (results  not shown). 
 
4.3  Prediction for real individuals: 
Note that  the above predictions  for generic individuals  can also be thought of as predictions  for a 
real individual  at  the  beginning  of the  therapy  when there  are no individual covariate  or follow-
up data available.  Once a subject  starts  to undergo  the  therapy,  the resulting information  on the 
progression of the treatment outcome can be used to predict her future  response to the treatment.  
This can be done as  the proposed model has the capacity to storage into its memory some key 
features of the earlier response of that  same subject,  both  observed and latent,  and then  use this 
information  in the predictions. 
 
Here we consider the second data  set, wherein follow-up information  was collected for two 
years.  Using observations  from the first year (of the two years’ of data)  for 5 selected individuals, 
and the results from our analysis of type-1 ccHRT based on data set-1, we made an attempt to 
predict how these 5 subjects would respond to the treatment after the  first year.  The  predictions  
were then  compared with  the  actual  observed data  from the second year for the same subject.  
The “N” episodes from the full two years’ data  for these five subjects are presented  in Figure 5. 
Note the distinctly  different response to the therapy of these five subjects undergoing the same 
HRT. 
 
(Figure-5 approximately here) 
 
For each of these five individuals  we computed  the predictive probabilities  for being in state  
“N” at different time points in the second year (Figure 6).  Observe from the first year’s data that,  
apart  from subject  4, the  others  had  experienced several “N” episodes of a short duration. 
However, the model is able to identify the characteristic differences between the  subjects quite  
well, with the  consequence that  the  predictive  probabilities differ from individual  to individual. 
 
(Figure-6 approximately here) 
 
Note in particular that  the improvement  observed in subject  2 in the second year is sudden  and  
entirely  different  in nature  than  the  “N”  episodes experienced  by the  this subject  in the first 
year.   However, the model successfully estimated  the latent state  of the subject  and gives a similar 
predictive probability  for being in state  “N” as to subject 4, who had responded well to the therapy  
during its entire course. 
 
Also note that  subject 3, who had initially shown improved response to the HRT with longer “N” 
episodes, gradually  experienced worsening in her condition  and several short episodes. The model 
gives her the lowest predictive probabilities  for “N” episodes among all five. 
 
5 Discussion 
 
We feel that our statistical model, combined with Bayesian inferential and computational methods in 
the estimation of its parameters, fulfils rather well the desiderata presented at the beginning of 
Section 3. In particular, the example considered above in Section 4.3 demonstrates that the method 
can provide realistic prognoses for an individual patient, when diary information from monitoring 
the condition of this patient is combined with corresponding background sample data. Such 
knowledge has some potential of being usefully applied in clinical practice, in which case it could be 
seen as a form of personalized medicine. On the other hand, we acknowledge that the computational 
burden in applying such a method is sizeable, which at present is likely to prevent its routine 
application for such a purpose. 
  There have been few methodological developments in this particular area in the recent literature. In 
related areas we have seen routine implementations of existing software (e.g. Gerlinger et al 2009), 
which however are unable to capture the complex heterogeneous structure of the problem. In the 
context of other applications, some efforts have been made to address similar problems in the 
classical (e.g. mazroui et al 2013) or in the Bayesian framework (e.g. Ding et al 2012, Pennell et al 
2010). 
 
While the construction of the model presented here was tailored to fit to considering HRTs and the 
particular data which were available to us, the above desiderata represent features which we would 
expect to be characteristic to numerous other interesting applications, and then shared in the 
corresponding data sets. These features include alternation, or more general changes, between two or 
more observable states for each considered individual or item, progressive development in its 
condition and corresponding transience in the sojourns in such states over time, non-Markovian 
dependence with respect to the observable states, and a high degree of heterogeneity of the 
individuals or items in the considered population.  
 
Among potential applications of this type one could include, for example, data collected from 
monitoring the use, maintenance and repair of some particular technical devices, data on 
employment histories with information on sick leaves, hospital stay data for patients with a 
particular chronic disease, or recidivism of criminal offences and jail sentences. Depending on the 
application in mind, it may be important to supplement the model with individual covariate data, an 
aspect which we have ignored in our present study of HRTs.  
 
The answers to the stated concrete questions are often most usefully given in the form of a 
probabilistic prediction of the future development of the considered process. A very special feature 
of our suggested approach is that such predictions can then be concerned with a particular 
individual, or be provided on the level of the considered background population. 
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 Figure Legends: 
 
Figure 1: Graphical presentation of the N (=1), S(=2) and B(=3) episodes (in vertical axes) 
against each day (in Y axes) for three selected individuals with comparable summary.  
 
Figure  2: Summaries based on “N” episodes from second data  set. 
 
Figure 3: Durations of “N” episodes of some selected individuals  from data  set-2. The 
horizontal axes present the number of the “N” episodes only, where the vertical axes represent 
duration in days. 
 
Figure 4: Predicted probability for “N” state  or otherwise at fixed time points for generic 
individuals undergoing different HRT regimes, with the estimated probability in Y axis and 
cumulative days under treatment presented in X-axis. 
 
Figure 5: Durations of “N” episodes for five selected individuals  from data  set 2.The 
horizontal axes represent the episode number, the vertical axes present the durations of each 
episode in days, with episodes from the first year marked in black and those from second year 
are in white. 
 
Figure 6:  Predictive probabilities  for being in state  “N” at different  time points in the second 
year (based on data  from first year only) for 5 individuals  from data  set 2. 
 
. 
 
 Table 1: For three randomly picked subjects, the number (and percentage)  of B, S and 
N days, along with the total durations and the number of episodes. 
Subject N days (%) S days (%) B days (% Total duration  
(No. of episodes) 
A 648 (90.0) 58 (8.1) 14 (1.9) 706 (69) 
B 650 (90.3) 70 (9.7) 0 (0.0) 720 (36) 
C 664 (92.2) 54 (7.5) 2 (0.3) 718 (9) 
 
Table 2: HRT specific posterior means of "phase probabilities" P00 for initially being in an "N" state, 
together with the corresponding conditional probabilities for then being in one of the four latent 
states (left box), and for initially being in a non-"N" state, with the corresponding conditional 
probabilities for then being in one of the three alternative observed states (right box). 
HRT Phase type N Phase type S/SB/B 
P00 P0 1-P00 P0  
 1 2 3 4  S SB B 
Type-1 ccHRT 0.37 0.07 0.09 0.28 0.56 0.63 0.82 0.14 0.04 
Type-2 ccHRT 0.34 0.11 0.17 0.17 0.56 0.67 0.81 0.13 0.06 
scHRT 0.98 0.02 0.66 0.31 0.01 0.02 0.18 0.76 0.06 
  
Table  3: HRT-specific posterior  means of state specific intensities β0,l  (for N-phase, l = 1, …, 4 ) 
and  β1,l (for non-N-phase, l = 1, 2, 3). 
HRT "N"-states
a
 Non-"N"-states 
1 2 3 4 S SB B 
Type-1 ccHRT     0.19 0.13 0.75 
Type-2 ccHRT 0.00 0.02 0.04 0.10 0.24 0.16 0.29 
scHRT     0.33 0.44 0.24 
a: The intensity is assumed to be same for all three HRTs, see model specification. 
 
Table  4: Posterior  means  of HRT specific two-step transition probabilities, P(l, 0, , ) for the “N”-
states (left), and P(l, 1, , )  for the “S/SB/B”-states (right).   
State N1 N2 N3 N4 State S SB B 
type-1 ccHRT 
N1 0.53 0.20 0.14 0.13 S 0.89 0.09 0.02 
N2 0.35 0.48 0.07 0.09 SB 0.63 0.33 0.03 
N3 0.04 0.22 0.35 0.40 B 0.18 0.09 0.73 
N4 0.02 0.31 0.07 0.59     
type-2 ccHRT 
N1 0.64 0.16 0.09 0.11 S 0.91 0.08 0.02 
N2 0.43 0.43 0.08 0.06 SB 0.81 0.19 0.00 
N3 0.17 0.22 0.39 0.22 B 0.71 0.14 0.14 
N4 0.02 0.16 0.07 0.75     
scHRT 
N1 0.27 0.12 0.41 0.19 S 0.44 0.54 0.02 
N2 0.04 0.56 0.32 0.07 SB 0.22 0.76 0.03 
N3 0.00 0.02 0.82 0.16 B 0.31 0.44 0.25 
N4 0.00 0.03 0.77 0.19     
 
Table  5: Results for a generic individual: HRT specific (posterior) predictive distribution for the 
time to cumulative amenorrhea, and the predicted proportions  of time spent in different states till 
cumulative amenorrhea. 
HRT Time to cumulative 
amenorrhea 
Proportions  of time spent 
Phase type N Phase type S/SB/B 
Median Mean 1 2 3 4 S SB B 
type-1 ccHRT 99.8 153.1 0.00 0.48 0.21 0.13 0.11 0.06 0.01 
type-2 ccHRT 75.1 121.4 0.00 0.47 0.20 0.15 0.11 0.05 0.02 
scHRT 327.7 535.7 0.00 0.23 0.56 0.07 0.03 0.04 0.01 
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